28 October 2019
Visiongain has launched a new pharma report Asia Vaccines Market Forecast to 2029 : Conjugate Vaccines, Inactivated and Subunit Vaccines, Live Attenuated Vaccines, Recombinant Vaccines, Toxoid Vaccines, Influenza, Hepatitis, Polio, Meningococcal, DTP, Rotavirus, MMR, HPV.
Globally, Asia is identified as a lucrative market for the vaccine development companies to establish and expand their presence in economies such as Japan, China and India. In addition, introduction of new technologies for development of innovative vaccines and rising government support also drive the market during the forecast period.
The lead analyst of the report commented "The vaccines market has witnessed a strong growth in the past few years, as the demand for vaccines is increasing in many Asian countries. Increased awareness for vaccination is one of the prominent factors driving the emerging market growth. This has led to intensified vaccination programmes for adolescents and growing geriatric population.
Japan accounted for the largest share of the vaccines market in Asia. Growth in the Japanese Vaccine market is driven by two main factors. First is the easing of Japan’s strict barriers to entry for foreign companies. Secondly, growth will be further driven by the population of elderly in Japan."
Leading companies featured in the report include Astellas, AstraZeneca
CSL, Ltd., Emergent BioSolutions, Inc., GlaxoSmithKline, Johnson & Johnson, Merck, Mitsubishi Tanabe Pharma Corporation, Pfizer, Sanofi, Serum Institute of India Pvt. Ltd., Sun Pharmaceuticals Industries, Ltd., Takeda and other companies.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The global Allergic Rhinitis Drugs market was valued at US$12,025.2 million in 2022 and is projected to grow at a CAGR of 3.78% during the forecast period 2023-2033.
30 January 2023
The global Women’s Health market was valued at US$36,567.3 million in 2022 and is projected to grow at a CAGR of 4.1% during the forecast period 2023-2033.
30 January 2023
The global Biodefence market was valued at US$14,675.0 million in 2022 and is projected to grow at a CAGR of 7.78% during the forecast period 2023-2033.
13 January 2023
The global Neurotech Devices market was valued at US$11,582.1 million in 2022 and is projected to grow at a CAGR of 13.78% during the forecast period 2023-2033.